🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06720922
Recruiting Not applicable

MRgLITT for mTLE: A PROBE Trial

NCT06720922 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tiantan Hospital
Phase
Not applicable
Started
2025-07-21
Last updated
2026-01-21

Condition(s) studied

Temporal Lobe Epilepsy (TLE)

Investigational drug(s) / intervention(s)

Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)Open Surgery

Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT): MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.

Open Surgery: Traditional Open Surgery

Study summary

How does magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) impact clinical prognosis in mesial temporal lobe epilepsy (mTLE)?

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * 18-65 years. * Drug-resistant mesial temporal lobe epilepsy. * Seizure frequency ≥ 1 time /month. * Participants approved. Exclusion Criteria: * History of brain surgery. * Intracranial space occupying lesions. * Individuals with significant medical comorbidities or conditions that pose an excessive risk for surgery, such as severe cardiovascular disease, respiratory disorders, or uncontrolled systemic infections.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tiantan Hospital Beijing Beijing Municipality Recruiting

More Beijing Tiantan Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06720922 on ClinicalTrials.gov ↗ ← All trials in China